PAGB welcomes reclassification of Otrivine Extra Dual Relief Nasal Spray Solution

Published on: 5 July 2017


Otrivine Extra Dual Relief Nasal Spray Solution, has been reclassified from a prescription only medicine (POM) to a Pharmacy (P) medicine in the UK, following a public consultation.

The nasal spray manufactured by GSK Consumer Healthcare, a PAGB member company, will be available to buy from pharmacies for the symptomatic treatment of nasal congestion and rhinorrhoea (runny nose) in connection with common colds, in adults 18 years and over.

In announcing the switch, MHRA reiterated its commitment to ‘improving access to medicines where it is safe to do so, providing greater choice and better access for the public’. PAGB welcomes the decision to reclassify Otrivine Extra Dual Relief Nasal Spray Solution from POM to P and is encouraged by the MHRA’s stance on this issue.

John Smith, PAGB CEO comments:

“Over-the-counter availability offers people faster and easier access to effective medicines and reduces pressure and costs on GPs. Where a medicine can show it has a good safety profile and the condition it treats is suitable for self care, reclassification is very positive and should be encouraged”